Vaxcyte, Inc. — Director's Dealing 2020

Jun 17, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2020-06-16

Reporting Person: Heron Patrick J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-16	Common Stock	C	1692494	—	Acquired	1692494	Indirect
2020-06-16	Common Stock	C	226236	—	Acquired	1918730	Indirect
2020-06-16	Common Stock	C	140824	—	Acquired	2059554	Indirect
2020-06-16	Common Stock	P	250000	$16.00	Acquired	2309554	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-16	Series B Preferred Stock	$	C	1692494	Disposed		Common Stock (1692494)	Indirect
2020-06-16	Series C Preferred Stock	$	C	226236	Disposed		Common Stock (226236)	Indirect
2020-06-16	Series D Preferred Stock	$	C	140824	Disposed		Common Stock (140824)	Indirect

Footnotes

F1: The Series B Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date.

F2: The shares are held of record by Frazier Life Sciences VIII, L.P. ("FLS VIII"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS VIII and FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. Patrick Heron and James Topper may be deemed to beneficially own the shares which are held by FLS VIII as they are the sole managing members of FHM LLC and therefore share voting and dispositive power over the shares held by FLS VIII. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.

F3: The Series C Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date.

F4: The Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering and had no expiration date.